The US FDA has issued warning letters to 30 telehealth companies for making misleading claims about compounded GLP-1 products on their websites.[1][2] These firms implied that their products were the same as FDA-approved drugs and hid the source of the drugs by selling them under their own brand without explanation.[1][4] This is the second wave of such letters since September, when the FDA began strictly controlling misleading direct-to-consumer advertising.[1][2] Over the past six months, the agency has sent thousands of warning letters to pharmaceutical and telehealth companies, more than in the entire previous decade.[1][2] Compounded drugs are not approved by the FDA, so their safety, efficacy, and quality are not tested before being marketed.[1] FDA Commissioner Marty Makary stated that compounded drugs can help address deficiencies or specific needs of patients, but must not bypass the approval process.[1][2] Telehealth companies do not prescribe drugs directly, but work with affiliated medical groups.[3] Recently, Hims & Hers withdrew its compounded semaglutide product following an FDA warning and a lawsuit from Novo Nordisk.[2]